Europe Benign Prostatic Hyperplasia Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy (Mono Drug Therapy and Combination Drug Therapy), By Therapeutics Class, By Country and Growth Forecast, 2021 - 2027

Europe Benign Prostatic Hyperplasia Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy (Mono Drug Therapy and Combination Drug Therapy), By Therapeutics Class, By Country and Growth Forecast, 2021 - 2027

The Europe Benign Prostatic Hyperplasia Therapeutics Market would witness market growth of 3.9% CAGR during the forecast period (2021-2027).

BPH is neither a malignancy nor a cause of prostate cancer. BPH, on the other hand, can be inconvenient and, in a number of instances, can lead to bladder obstruction. It appears to be a natural part of the aging process, affecting men over the age of 40. Benign prostate hyperplasia is characterized by the presence of discrete nodules in the periurethral zone of the prostate gland.

To treat BPH symptoms, drugs such as alpha-blockers, 5-alpha reductase inhibitors, and phosphodiesterase-5 inhibitors are employed. These treatments relax the smooth bladder muscles or reduce the abnormal prostate growth. The prostate's grasp on the urethra loosens as bladder muscles relax, enabling urine to flow more freely. Prostate shrinking, on the other hand, lessens the pressure produced by the prostate on the urethra, allowing urine to flow freely.

Despite the fact that 40% of men over the age of 60 have an enlarged prostate, a new poll published by the European Association of Urology (EAU) has shown that awareness of prostate health is disturbingly low among men over 50. Only 38% of respondents correctly identified the disease (beneficial prostate enlargement (BPE) or hyperplasia (BPH)). The main purpose of a healthy prostate, which is around the size of a walnut, is to produce prostatic fluid, which is used to transport sperm. Despite the fact that it grows slowly as men age, just one in six (17%) respondents correctly said that symptoms associated with an enlarged prostate are not a "typical" indicator of aging.

The Germany market dominated the Europe Benign Prostatic Hyperplasia Therapeutics Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $481.1 million by 2027. The UK market would experience a CAGR of 3.1% during (2021 - 2027). Additionally, The France market is anticipated to grow a CAGR of 4.6% during (2021 - 2027).

Based on Therapy, the market is segmented into Mono Drug Therapy and Combination Drug Therapy. Based on Therapeutics Class, the market is segmented into Alpha Blockers, 5- alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Astellas Pharma, Inc., Eli Lilly and Company, Allergan PLC (AbbVie), Merck Group (Merck Sharp & Dohme Corp.), Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Pfizer, Inc., and Abbott Laboratories.

Scope of the Study

Market Segments covered in the Report:

By Therapy

  • Mono Drug Therapy
  • Combination Drug Therapy
By Therapeutics Class
  • Alpha Blockers
  • 5- alpha Reductase Inhibitors
  • Phosphodiesterase-5 Inhibitors
  • Others
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • GlaxoSmithKline PLC (GSK)
  • Astellas Pharma, Inc.
  • Eli Lilly and Company
  • Allergan PLC (AbbVie)
  • Merck Group (Merck Sharp & Dohme Corp.)
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceuticals Industries Ltd.
  • Sanofi S.A.
  • Pfizer, Inc.
  • Abbott Laboratories
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Benign Prostatic Hyperplasia Therapeutics Market, by Therapy
1.4.2 Europe Benign Prostatic Hyperplasia Therapeutics Market, by Therapeutics Class
1.4.3 Europe Benign Prostatic Hyperplasia Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy
3.1 Europe Mono Drug Therapy Market by Country
3.2 Europe Combination Drug Therapy Market by Country
Chapter 4. Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
4.1 Europe Alpha Blockers Market by Country
4.2 Europe 5- alpha Reductase Inhibitors Market by Country
4.3 Europe Phosphodiesterase-5 Inhibitors Market by Country
4.4 Europe Others Market by Country
Chapter 5. Europe Benign Prostatic Hyperplasia Therapeutics Market by Country
5.1 Germany Benign Prostatic Hyperplasia Therapeutics Market
5.1.1 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.1.2 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.2 UK Benign Prostatic Hyperplasia Therapeutics Market
5.2.1 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.2.2 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.3 France Benign Prostatic Hyperplasia Therapeutics Market
5.3.1 France Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.3.2 France Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.4 Russia Benign Prostatic Hyperplasia Therapeutics Market
5.4.1 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.4.2 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.5 Spain Benign Prostatic Hyperplasia Therapeutics Market
5.5.1 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.5.2 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.6 Italy Benign Prostatic Hyperplasia Therapeutics Market
5.6.1 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.6.2 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.7 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market
5.7.1 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.7.2 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
Chapter 6. Company Profiles
6.1 GlaxoSmithKline PLC (GSK)
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Astellas Pharma, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Regional Analysis
6.2.4 Research & Development Expense
6.3 Eli Lilly and Company
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expense
6.4 Allergan PLC (AbbVie)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.5 Merck Group (Merck Sharp & Dohme Corp.)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Boehringer Ingelheim International Gmbh
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional & Segmental Analysis
6.6.4 Research & Development Expenses
6.7 Teva Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expenses
6.8 Sanofi S.A.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.10. Abbott Laboratories
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings